“Softer” Mass Spec Techniques Gain Advantage in Biomarker Discovery
|
By LabMedica International staff writers Posted on 29 Mar 2015 |
|
Two mass spectrometry (MS) technologies, MALDI and DESI, are increasing in applications as their effectiveness is established, according to Kalorama Information (New York, NY, USA) in its report “Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies).”
MS is the most powerful tool in proteomic biomarker discovery and validation. Through its traditional techniques MS has struggled to elucidate tissue molecular distribution related to disease state. In recent years, MS imaging, including MALDI and DESI imaging, has seen significant application in proteomic biomarker discovery with its distinct advantages in preservation of spatial proteomic data and potential to improve assay reproducibility.
In MALDI and DESI, nondestructive techniques are utilized with soft ionization sources to desorb and ionize surface molecules for MS analysis. According to Kalorama, one of the key strengths of MALDI and DESI is that they avoid traditional tissue sample preparation, a tedious front-end process that presents a significant bottleneck in proteomics where differential analysis is used to compare protein expression and abundance between samples. Proteolytic digestion and other sample preparation procedures remove significant analytical context value related to protein spatial distribution and concentration.
Kalorama believes that a number of studies have cemented the reputation of these MS technologies. Researchers have noted the novelty of MALDI imaging of tissue (introduced in 1997) to discover proteins otherwise difficult to separate by electrophoresis or hidden in shotgun proteomic processes that are biased towards higher-mass proteins. Recent studies have used MALDI imaging to discover several biomarkers associated with gastric cancer survival prognosis, forms of ovarian cancer, and to develop a novel grading system for papillary non-invasive bladder cancer.
Kalorama’s report contains breakouts of the market by type of technology used and application. It profiles companies and surveys partnerships and deals related to proteomics.
Related Links:
Kalorama Information
Proteomics Markets for Research and IVD Applications, report
MS is the most powerful tool in proteomic biomarker discovery and validation. Through its traditional techniques MS has struggled to elucidate tissue molecular distribution related to disease state. In recent years, MS imaging, including MALDI and DESI imaging, has seen significant application in proteomic biomarker discovery with its distinct advantages in preservation of spatial proteomic data and potential to improve assay reproducibility.
In MALDI and DESI, nondestructive techniques are utilized with soft ionization sources to desorb and ionize surface molecules for MS analysis. According to Kalorama, one of the key strengths of MALDI and DESI is that they avoid traditional tissue sample preparation, a tedious front-end process that presents a significant bottleneck in proteomics where differential analysis is used to compare protein expression and abundance between samples. Proteolytic digestion and other sample preparation procedures remove significant analytical context value related to protein spatial distribution and concentration.
Kalorama believes that a number of studies have cemented the reputation of these MS technologies. Researchers have noted the novelty of MALDI imaging of tissue (introduced in 1997) to discover proteins otherwise difficult to separate by electrophoresis or hidden in shotgun proteomic processes that are biased towards higher-mass proteins. Recent studies have used MALDI imaging to discover several biomarkers associated with gastric cancer survival prognosis, forms of ovarian cancer, and to develop a novel grading system for papillary non-invasive bladder cancer.
Kalorama’s report contains breakouts of the market by type of technology used and application. It profiles companies and surveys partnerships and deals related to proteomics.
Related Links:
Kalorama Information
Proteomics Markets for Research and IVD Applications, report
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Latest BioResearch News
- Study Identifies Protein Changes Driving Immunotherapy Resistance in Multiple Myeloma
- Genetic Analysis Identifies BRCA-Linked Risks Across Multiple Cancers
- Study Identifies Hidden B-Cell Mutations in Autoimmune Disease
- Single-Cell Method Measures RNA and Proteins to Reveal Immune Responses
- Study Links Midlife Vitamin D to Lower Tau in Alzheimer's
- International Consensus Standardizes Tumor Microbiota Detection and Reporting
- Common Metablolic Enzyme Could Predict Response to Cancer Immunotherapy
- Newly Identfied Genetic Variants in MND Support Prognosis and Family Testing
- Innate Immunity Variants Associated With Earlier Breast Cancer in BRCA1 Carriers
- Genetic Cause Identified for Severe Infant Epilepsy
- Study Reveals Diagnostic and Therapeutic Target in Rare Pancreatic Tumors
- Researchers Identify Survival Pathway Undermining Targeted Cancer Drugs
- Large-Scale Study Maps DNA Damage Signatures Across Multiple Cancers
- Study Identifies Distinct Immune Signatures to Early Depression and Psychosis
- Genetic Mutation Behind Aggressive Adult Leukemia Offers Treatment Clues
- Disease Gene Discovery Advances Diagnosis of Rare Movement Disorders
Channels
Clinical Chemistry
view channel
Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection
Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Molecular Diagnostics
view channel
Cancer-Related Mutations in Immune Cells Linked to Alzheimer’s
Alzheimer’s disease is marked by protein aggregation and inflammatory changes in the brain’s immune system, yet its molecular drivers remain incompletely understood. With aging, human cells accumulate... Read more
Composite Blood Biomarkers Enable Early Detection of Common Cancers
Early diagnosis of colorectal, lung, and ovarian cancers remains challenging, with many patients identified only after tumors have begun to spread. A scalable blood test could expand access to screening,... Read more
Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary
Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Hematology
view channel
Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
CareDx (Brisbane, CA, USA) has introduced AlloSeq Nano, a nanopore‑based HLA (human leukocyte antigen) and ABO genotyping solution unveiled at the European Federation for Immunogenetics (EFI) Conference 2026.... Read more
Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and often presents with aggressive clinical behavior. Although many patients respond to standard chemotherapy with... Read more
Immunology
view channel
Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read more
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read more
Microbiology
view channel
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read more
Label-Free Microscopy Methodd Enables Faster, Quantitative Detection of Malaria
Microscopy of blood smears remains a cornerstone for malaria diagnosis but can be slow, stain-dependent, and operator intensive. With more than 200 million infections and over 600,000 deaths annually,... Read more
Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
Melanoma remains prone to relapse even after surgery and adjuvant immunotherapy, with 25% to 40% of patients experiencing recurrence. Clinicians lack reliable pre-treatment indicators to identify those... Read more
Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
Gram-negative bloodstream infections and sepsis demand fast, precise antimicrobial therapy, yet conventional susceptibility workflows can delay targeted treatment. Clinical laboratories need platforms... Read morePathology
view channel
Plug-and-Play AI Pathology System Classifies Multiple Cancers from Few Slides
Pathologists are essential for cancer diagnosis and treatment planning, yet a global workforce shortage is straining services. Nearly 20 million new cases are diagnosed each year, and traditional artificial... Read more
AI-Based Assays Support Risk Stratification in Prostate and Breast Cancer
Prostate and breast cancers are among the most commonly diagnosed malignancies worldwide, and heterogeneous disease biology complicates risk stratification and treatment selection. Clinicians increasingly... Read more
Technology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read more
Industry
view channel
QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more
Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
Seegene introduced STAgora, a real-time data analytics platform built on aggregated statistical testing data, at ESCMID Global 2026 in Munich, where it also presented an enhanced model of its automated... Read more
Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more